(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 16.25% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.28%.
Exagen's revenue in 2026 is $63,599,000.On average, 9 Wall Street analysts forecast XGN's revenue for 2026 to be $1,746,735,692, with the lowest XGN revenue forecast at $1,581,340,396, and the highest XGN revenue forecast at $1,929,876,195. On average, 7 Wall Street analysts forecast XGN's revenue for 2027 to be $1,971,191,025, with the lowest XGN revenue forecast at $1,783,449,913, and the highest XGN revenue forecast at $2,191,634,989.
In 2028, XGN is forecast to generate $2,298,038,239 in revenue, with the lowest revenue forecast at $2,152,133,207 and the highest revenue forecast at $2,472,544,101.